Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare progressive disease that begins as a primary Epstein-Barr virus (EBV) infection. In this type of infection, the body makes too many lymphocytes (lymphoproliferative disease) for a period of more than 6 months duration. Lymphocytes are a type of white blood cell. They are an importantpart ofthe immune system because they help fight off diseases and protect the body from infection byproducing antibodies against viruses or bacteria and regulating immune responses. In CAEBV there are many antibodies againstEBV in the blood.Most people (about 95% of adults) get infected with EBV at some point in their lives, and never have any health problems.However, EBV can cause infectiousmononucleosis and other illnesses, and has a role in various autoimmune diseases and some types of cancer. While most infections occurring during childhood do not cause any symptoms,EBV infection in adolescents or young adults can often result in mononucleosis.After an EBV infection, the virus becomes latent (inactive) in the body, and, in some cases, the virus may reactivate. This does not always cause symptoms, but people with weakened immune systems are more likely to develop symptoms if EBV reactivates.In rare cases, people infected with EBV develop chronic active EBV virus infection(CAEBV) without apparent immunodeficiency. Most cases of CAEBV have been reported from Japan. These patientshave some of the complications found in otherwise-healthy patients with acute EBV infection, but unlike healthy patients, these complications persist and progress. Symptoms of CAEBV most often include fever, liverdysfunction, an enlarged spleen (splenomegaly), swollen lymph nodes (lymphadenopathy), and low numbers of platelets (thrombocytopenia) as well as high EBV-DNA load in the blood. Other features that appear in more than 10% of patients include enlarged liver (hepatomegaly), anemia, hypersensitivity to mosquito bites, rash, oral ulcers, hemophagocytic syndrome, coronary artery aneurysms, liver failure, lymphoma, and interstitial pneumonia. While the cause is yet unknown, researchers have identified defects in T cells or natural killer (NK) cells activity which results in a decreased defense against the EBV in people with CAEBV.It is important to note that the fatigue and malaise from acute infectious mononucleosis (IM)varies from mild symptoms lasting only a few weeks, to more severe symptoms of fatigue that can persist for several months, or even up to a year or more in up to 10% of patients (which may be considered a less severe form of chronicEBV infection). The persistence of fatigue that is seen in some patients after acute IM would lead some people to believe that EBV may also cause cases of chronic fatigue syndrome (CFS). However, no convincing link has been found between EBV and CFS.Hematopoietic stemcell transplantation has shown promise in the treatment of CAEBV.
Features include always present findings: Increased total eosinophil count, Decreased neutrophil oxidative burst, BCGitis, and Enlarged liver (hepatomegaly) and others. 21 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 8 | Decreased neutrophil oxidative burst, Increased total neutrophil count, Recurrent infections |
Lungs and breathing | 3 | Bronchiectasis, Pneumonia, Recurrent respiratory infections |
Digestive system | 2 | Enlarged liver (hepatomegaly), Enlarged spleen (splenomegaly) |
Growth and development | 1 | Failure to thrive |
Metabolism | 1 | Fever |
Brain and nerves | 1 | Cerebral calcification |
IRF8 encodes interferon regulatory factor 8 (426 aa). Transcription factor that specifically binds to the upstream regulatory region of type I interferon (IFN) and IFN-inducible MHC class I genes (the interferon consensus sequence (ICS)). Highest expression in Cells EBV-transformed lymphocytes (136.0 TPM) and Spleen (107.3 TPM).
Immunodeficiency 32B is associated with mutations in the IRF8 gene on chromosome 16.
The IRF8 protein participates in TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling pathway.
IRF8 is classified as a druggable target (Clinically Actionable and Transcription Factor categories) with score 0.0.
Genetic testing for IRF8 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for immunodeficiency 32B has been reported in the published literature.
Phenotype severity distribution: 14 always present features.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for immunodeficiency 32B.
92 publications have been identified in PubMed for immunodeficiency 32B. Research spans Case Report / Case Series (29%), Review / Meta-Analysis (23%), and Basic Science / Preclinical (20%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 27 | 29% |
Research summaries | 21 | 23% |
Laboratory research | 18 | 20% |
Disease patterns and progression | 17 | 18% |
Clinical study results | 5 | 5% |
Other research | 2 | 2% |
Testing and diagnosis research | 2 | 2% |
Maccari ME (2026). [PMID: 42136947](https://pubmed.ncbi.nlm.nih.gov/42136947/). *J Hum Immun*. [Basic Science / Preclinical]
Eren Akarcan S (2026). [PMID: 41998580](https://pubmed.ncbi.nlm.nih.gov/41998580/). *BMC Pediatr*. [Case Report / Case Series]
Leite-Aguiar R (2026). [PMID: 40364625](https://pubmed.ncbi.nlm.nih.gov/40364625/). *Neural regeneration research*. [Basic Science / Preclinical]
Sun S (2026). [PMID: 41961712](https://pubmed.ncbi.nlm.nih.gov/41961712/). *Medicine (Baltimore)*. [Epidemiology / Natural History]
Opala D (2026). [PMID: 42222634](https://pubmed.ncbi.nlm.nih.gov/42222634/). *Cureus*. [Case Report / Case Series]
Duan M (2026). [PMID: 42084291](https://pubmed.ncbi.nlm.nih.gov/42084291/). *J Med Virol*. [Review / Meta-Analysis]
Almulla AF (2026). [PMID: 42125999](https://pubmed.ncbi.nlm.nih.gov/42125999/). *Immun Inflamm Dis*. [Basic Science / Preclinical]
Boichuk I (2026). [PMID: 41996262](https://pubmed.ncbi.nlm.nih.gov/41996262/). *Cesk Patol*. [Case Report / Case Series]
Tack M (2026). [PMID: 41901562](https://pubmed.ncbi.nlm.nih.gov/41901562/). *Medicina (Kaunas)*. [Epidemiology / Natural History]
Farooqui SA (2026). [PMID: 42193931](https://pubmed.ncbi.nlm.nih.gov/42193931/). *Cells*. [Review / Meta-Analysis]
Data assembled from 6 of 12 sources · Last updated Sep 18, 2026, 7:12 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning immunodeficiency 32B
Updated Feb 27, 2026
A recent study highlights the combined impact of common and rare genetic variants on the risk of inflammatory bowel disease in patients with immunodeficiency. This research could inform future genetic screening and risk assessment strategies.